Caribou Biosciences, Inc.
NASDAQ:CRBUBiotechnology
-$0.05 today
- Market cap
- $52.47M
- Beta
- 2.33
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$1.39
Volume 1.01M
Average 1.83M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Caribou Biosciences, Inc.
NASDAQ:CRBU
Intrinsic Alpha fair value
Locked
Current Price
$0.49
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -7.0% | +53.5% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at -7.0% over three years. Forward estimates point to Revenue at +53.5% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Allogene Therapeutics, Inc. NASDAQ:ALLO | $452.59M | $1.31 | Not rated | -2.7 | -43.20% |
Orchestra BioMed Holdings, Inc. NASDAQ:OBIO | $327.57M | $5.45 | Not rated | -2.8 | +64.78% |
Enanta Pharmaceuticals, Inc. NASDAQ:ENTA | $323.29M | $11.10 | Not rated | -4.3 | -29.69% |
Prelude Therapeutics Incorporated NASDAQ:PRLD | $260.16M | $3.26 | Not rated | -4.5 | +97.62% |
Inventiva S.A. NASDAQ:IVA | $152.83M | $2.94 | Not rated | -5.5 | -22.97% |
Humacyte, Inc. NASDAQ:HUMA | $119.18M | $0.43 | Not rated | -1.9 | -58.25% |
Foghorn Therapeutics Inc. NASDAQ:FHTX | $109.86M | $1.85 | Not rated | -3.8 | -63.55% |
Pyxis Oncology, Inc. NASDAQ:PYXS | $106.44M | $1.68 | Not rated | -1.6 | -69.49% |
Tenaya Therapeutics, Inc. NASDAQ:TNYA | $85.36M | $0.38 | Not rated | -1.3 | -74.78% |
Aardvark Therapeutics, Inc. Common Stock NASDAQ:AARD | $82.72M | $3.78 | Not rated | -1.2 | -59.86% |
Continue the stock analysis
Jump to another research area for this company.